130 related articles for article (PubMed ID: 31020859)
1. Silymarin as a flavonoid-type P-glycoprotein inhibitor with impact on the pharmacokinetics of carbamazepine, oxcarbazepine and phenytoin in rats.
Ferreira A; Rodrigues M; Meirinho S; Fortuna A; Falcão A; Alves G
Drug Chem Toxicol; 2021 Sep; 44(5):458-469. PubMed ID: 31020859
[TBL] [Abstract][Full Text] [Related]
2. Influence of the dual combination of silymarin and (-)-epigallocatechin gallate, natural dietary flavonoids, on the pharmacokinetics of oxcarbazepine in rats.
Ferreira A; Rodrigues M; Marques A; Falcão A; Alves G
Food Chem Toxicol; 2017 Aug; 106(Pt A):446-454. PubMed ID: 28602600
[TBL] [Abstract][Full Text] [Related]
3. Flavonoid compounds as reversing agents of the P-glycoprotein-mediated multidrug resistance: An in vitro evaluation with focus on antiepileptic drugs.
Ferreira A; Rodrigues M; Fortuna A; Falcão A; Alves G
Food Res Int; 2018 Jan; 103():110-120. PubMed ID: 29389596
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein alters blood-brain barrier penetration of antiepileptic drugs in rats with medically intractable epilepsy.
Ma A; Wang C; Chen Y; Yuan W
Drug Des Devel Ther; 2013; 7():1447-54. PubMed ID: 24348021
[TBL] [Abstract][Full Text] [Related]
5. In vitro screening of dual flavonoid combinations for reversing P-glycoprotein-mediated multidrug resistance: Focus on antiepileptic drugs.
Ferreira A; Santos AO; Falcão A; Alves G
Food Chem Toxicol; 2018 Jan; 111():84-93. PubMed ID: 29122665
[TBL] [Abstract][Full Text] [Related]
6. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats.
Potschka H; Löscher W
Epilepsia; 2001 Oct; 42(10):1231-40. PubMed ID: 11737157
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients.
McKee PJ; Blacklaw J; Forrest G; Gillham RA; Walker SM; Connelly D; Brodie MJ
Br J Clin Pharmacol; 1994 Jan; 37(1):27-32. PubMed ID: 8148215
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.
Lin WW; Li XW; Jiao Z; Zhang J; Rao X; Zeng DY; Lin XH; Wang CL
Eur J Clin Pharmacol; 2019 Mar; 75(3):381-392. PubMed ID: 30456415
[TBL] [Abstract][Full Text] [Related]
9. Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers.
Antunes Nde J; Wichert-Ana L; Coelho EB; Della Pasqua O; Alexandre Junior V; Takayanagui OM; Tozatto E; Marques MP; Lanchote VL
Eur J Clin Pharmacol; 2016 Feb; 72(2):195-201. PubMed ID: 26514967
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.
Battino D; Estienne M; Avanzini G
Clin Pharmacokinet; 1995 Nov; 29(5):341-69. PubMed ID: 8582119
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: new set of data for predictive in silico ADME models.
Fortuna A; Alves G; Soares-da-Silva P; Falcão A
Epilepsy Res; 2013 Nov; 107(1-2):37-50. PubMed ID: 24050973
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the permeability and P-glycoprotein efflux of carbamazepine and several derivatives across mouse small intestine by the Ussing chamber technique.
Fortuna A; Alves G; Falcão A; Soares-da-Silva P
Epilepsia; 2012 Mar; 53(3):529-38. PubMed ID: 22372629
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects.
Antunes NJ; van Dijkman SC; Lanchote VL; Wichert-Ana L; Coelho EB; Alexandre Junior V; Takayanagui OM; Tozatto E; van Hasselt JGC; Della Pasqua O
Eur J Pharm Sci; 2017 Nov; 109S():S116-S123. PubMed ID: 28528287
[TBL] [Abstract][Full Text] [Related]
14. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
Baltes S; Gastens AM; Fedrowitz M; Potschka H; Kaever V; Löscher W
Neuropharmacology; 2007 Feb; 52(2):333-46. PubMed ID: 17045309
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic interactions of valproate, phenytoin, phenobarbitone and carbamazepine with curcumin in experimental models of epilepsy in rats.
Reeta KH; Mehla J; Pahuja M; Gupta YK
Pharmacol Biochem Behav; 2011 Sep; 99(3):399-407. PubMed ID: 21641922
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy.
Wang Y; Zhang HN; Niu CH; Gao P; Chen YJ; Peng J; Liu MC; Xu H
Acta Pharmacol Sin; 2014 Oct; 35(10):1342-50. PubMed ID: 25220641
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain.
Potschka H; Fedrowitz M; Löscher W
Neuroreport; 2001 Nov; 12(16):3557-60. PubMed ID: 11733711
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics of oxcarbazepine.
May TW; Korn-Merker E; Rambeck B
Clin Pharmacokinet; 2003; 42(12):1023-42. PubMed ID: 12959634
[TBL] [Abstract][Full Text] [Related]
19. Chronic administration of phenytoin induces efflux transporter overexpression in rats.
Alvariza S; Fagiolino P; Vázquez M; Feria-Romero I; Orozco-Suárez S
Pharmacol Rep; 2014 Dec; 66(6):946-51. PubMed ID: 25443719
[TBL] [Abstract][Full Text] [Related]
20. Oxcarbazepine.
Tecoma ES
Epilepsia; 1999; 40 Suppl 5():S37-46. PubMed ID: 10530693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
